Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39587| Title: | Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients. | Authors: | Williams T.;McLean C.A.;Butler E. ;Fok A. | Institution: | (Fok) Department of Ophthalmology & Visual Sciences, Faculty of Medicine, Eye Care Centre (Vancouver General Hospital), Vancouver, BC, Canada (Fok, Butler) Department of Neurosciences, Monash Health, Melbourne, VIC, Australia (Williams) Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, VIC, Australia (McLean) Department of Anatomical Pathology, Alfred Hospital, Melbourne, VIC, Australia | Issue Date: | 27-Dec-2017 | Copyright year: | 2016 | Publisher: | SAGE Publications Ltd (E-mail: info@sagepub.co.uk) | Place of publication: | United Kingdom | Publication information: | Multiple Sclerosis Journal. 22 (11) (pp 1495-1498), 2016. Date of Publication: 01 Oct 2016. | Journal: | Multiple Sclerosis Journal | Abstract: | We report two patients with relapsing remitting multiple sclerosis (RRMS) on interferon (IFN) beta-1a treatment for more than 7 years who developed pulmonary arterial hypertension (PAH). Patient 1 developed severe PAH requiring lung transplantation. Histology showed typical proliferative lesions including plexiform lesions consistent with PAH. Patient 2 ceased IFN beta-1a, and their symptoms stabilised. Both cases highlight IFN beta-1a treatment as a potential risk factor for PAH. PAH needs to be considered as a diagnosis in patients on long-term IFN beta-1a treatment who develop new-onset respiratory symptoms.Copyright © The Author(s), 2015. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1177/1352458515618020 | Link to associated publication: | Click here for full text options | ISSN: | 1352-4585 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/39587 | Type: | Article | Subjects: | electrocardiography Expanded Disability Status Scale heart atrium enlargement/di [Diagnosis] heart catheterization heart right atrium pressure histopathology human human tissue hypertrophy hypoxemia/th [Therapy] immunosuppressive treatment *long term care lung diffusion capacity lung transplantation lung vascular resistance lung wedge pressure maximum tolerated dose middle aged *multiple sclerosis/di [Diagnosis] *multiple sclerosis/dt [Drug Therapy] multiple sclerosis/dt [Drug Therapy] New York Heart Association class oxygen therapy *pulmonary hypertension/di [Diagnosis] *pulmonary hypertension/dt [Drug Therapy] *pulmonary hypertension/si [Side Effect] pulmonary hypertension/dt [Drug Therapy] pulmonary hypertension/si [Side Effect] *beta1a interferon/dt [Drug Therapy] bosentan/dt [Drug Therapy] diltiazem/dt [Drug Therapy] fingolimod/dt [Drug Therapy] hematoxylin hydrochlorothiazide/dt [Drug Therapy] perindopril/dt [Drug Therapy] prostacyclin/dt [Drug Therapy] prostacyclin/iv [Intravenous Drug Administration] sildenafil/dt [Drug Therapy] sildenafil/iv [Intravenous Drug Administration] sitaxsentan/dt [Drug Therapy] sitaxsentan/iv [Intravenous Drug Administration] teriflunomide/dt [Drug Therapy] warfarin/dt [Drug Therapy] heart right atrium enlargement/di [Diagnosis] heart right ventricular systolic dysfunction/di [Diagnosis] female risk factor six minute walk test thorax radiography transthoracic echocardiography treatment duration ambrisentan/dt [Drug Therapy] *beta1a interferon/ae [Adverse Drug Reaction] adult article cardiomegaly case report clinical article drug substitution drug tolerability dyspnea echocardiography female heart atrium enlargement / diagnosis heart catheterization heart right atrium pressure histopathology human human tissue hypertrophy hypoxemia / therapy immunosuppressive treatment *long term care lung diffusion capacity lung transplantation lung vascular resistance lung wedge pressure maximum tolerated dose middle aged *multiple sclerosis / *diagnosis / *drug therapy multiple sclerosis / drug therapy New York Heart Association class oxygen therapy *pulmonary hypertension / *diagnosis / *drug therapy / *side effect pulmonary hypertension / drug therapy / side effect risk factor six minute walk test thorax radiography transthoracic echocardiography treatment duration cardiomegaly Article case report adult clinical article drug substitution drug tolerability dyspnea echocardiography electrocardiography Expanded Disability Status Scale |
Type of Clinical Study or Trial: | Case series or case report |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.